Sclerosis: all 3,103 studies

Page 8 of 32. Open to participants first (314), then studies with results posted, then the rest; newest registration first within each.

• A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple SclerosisCompletedNCT01247324Phase 3Results posted
• Lubiprostone in Patients With Multiple Sclerosis Associated ConstipationCompletedNCT01236534Phase 4Results posted
• Trial of Safety and Efficacy of Rasagiline in Patients With Amyotrophic Lateral Sclerosis (ALS)CompletedNCT01232738Phase 2Results posted
• Phase 2 Extension Trial in Patients With Relapsing-Remitting Multiple Sclerosis (RRMS)TerminatedNCT01226745Phase 2Results posted
• Impact of Vitamin A Supplementation on Immune System in Multiple Sclerosis PatientsCompletedNCT01225289Phase 4Results posted
• A 6-month, Randomized, Open-label, Patient OutComes, Safety and Tolerability Study of Fingolimod (FTY720) 0.5 mg/Day vs. Comparator in Patients With Relapsing Forms of Multiple SclerosisCompletedNCT01216072Phase 4Results posted
• Study of Induction Therapy With Mitoxantrone and Plasmapheresis to Treat Aggressive Multiple SclerosisCompletedNCT01214317Not applicableResults posted
• Double Blind Combination of Rituximab by Intravenous and Intrathecal Injection Versus Placebo in Patients With Low-Inflammatory Secondary Progressive Multiple Sclerosis (RIVITaLISe)TerminatedNCT01212094Phase 1/2Results posted
• Retrospective Cohort Study of Rebif® Use in Pediatric Multiple Sclerosis (MS) Subjects (REPLAY)CompletedNCT01207648Results posted
• Long-term Safety and Tolerability of 0.5 mg Fingolimod in Patients With Relapsing Forms of Multiple SclerosisCompletedNCT01201356Phase 3Results posted
• Evaluation of Emotional Disorders During Treatment by Interferon Beta in Relapsing-remitting Multiple Sclerosis PatientsCompletedNCT01201343Phase 4Results posted
• Effect of Treatment With Fingolimod on the Immune Response Following Seasonal Flu Vaccination and Tetanus Booster Injection in Patients With Relapsing Multiple Sclerosis (MS)CompletedNCT01199861Phase 3Results posted
• Telehealth-Based Exercise Program to Treat Fatigue in MSCompletedNCT01198977Not applicableResults posted
• A Multicentre Study of the Efficacy and Safety of Supplementary Treatment With Cholecalciferol in Patients With Relapsing Multiple Sclerosis Treated With Subcutaneous Interferon Beta-1a 44 µg 3 Times WeeklyCompletedNCT01198132Phase 2Results posted
• A Study of Ocrelizumab in Participants With Primary Progressive Multiple SclerosisCompletedNCT01194570Phase 3Results posted
• Lipoic Acid for Secondary Progressive Multiple Sclerosis (MS)CompletedNCT01188811Phase 2/3Results posted
• Long-term Safety, Tolerability and Efficacy of BAF312 Given Orally in Patients With Relapsing-remitting Multiple SclerosisCompletedNCT01185821Phase 2Results posted
• Evaluation of Two Glatiramer Acetate (GA) Formulations in Relapsing-Remitting Multiple Sclerosis (RRMS) PatientsCompletedNCT01167426Phase 3Results posted
• Zoledronic Acid in MS-patients With OsteoporosisTerminatedNCT01166178Phase 3Results posted
• Nilotinib in the Treatment of Systemic SclerosisCompletedNCT01166139Phase 2Results posted
• BG00012 Phase 2 Combination Study in Participants With Multiple SclerosisCompletedNCT01156311Phase 2Results posted
• Study of Standard Noninvasive Positive Pressure Ventilation (NIPPV) and Low Expiratory Pressure NIPPV in ALS PatientsCompletedNCT01154283Not applicableResults posted
• Natalizumab De-escalation With Interferon Beta-1bCompletedNCT01144052Phase 4Results posted
• A Phase IV Study of Rebif ® 44mcg Administered Three Times Per Week by Subcutaneous Injection Compared With no Treatment in the Therapy of Relapsing Multiple Sclerosis After MitoxantroneCompletedNCT01142466Phase 4Results posted
• Minocycline as add-on to Interferon Beta-1a [IFN Beta-1a] (Rebif®) in Relapsing-Remitting Multiple Sclerosis [RRMS]TerminatedNCT01134627Phase 2Results posted
• A P300 Brain Computer Interface Keyboard to Control Assistive Technology For Use by People With Amyotrophic Lateral SclerosisCompletedNCT01119001Not applicableResults posted
• A Cooperative Clinical Study of Abatacept in Multiple SclerosisCompletedNCT01116427Phase 2Results posted
• ATX-MS-1467 in Patients With Relapsing Forms of Multiple SclerosisCompletedNCT01097668Phase 1Results posted
• Study of Ambrisentan With Antifibrotic Agent Combination Therapy in Diffuse Systemic SclerosisCompletedNCT01093885Not applicableResults posted
• Clinical Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Ponesimod in Patients With Relapsing-remitting Multiple SclerosisCompletedNCT01093326Phase 2Results posted
• Rituximab for Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH)CompletedNCT01086540Phase 2Results posted
• Rebif Advanced Magnetic Resonance Imaging (MRI) and Immunology Pilot TrialCompletedNCT01085318Phase 4Results posted
• SOD1 Inhibition by Pyrimethamine in Familial Amyotrophic Lateral Sclerosis (ALS)CompletedNCT01083667Phase 1/2Results posted
• Tysabri Effects on Cognition and Neurodegeneration in Multiple SclerosisCompletedNCT01071512Not applicableResults posted
• Everolimus (RAD001) Therapy for Epilepsy in Patients With Tuberous Sclerosis Complex (TSC)CompletedNCT01070316Phase 1/2Results posted
• A Study in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) to Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) Injection 40 mg Administered Three Times a Week Compared to PlaceboCompletedNCT01067521Phase 3Results posted
• Efficacy and Safety of BIIB019 (Daclizumab High Yield Process) Versus Interferon β 1a in Participants With Relapsing-Remitting Multiple SclerosisCompletedNCT01064401Phase 3Results posted
• Study Evaluating Rebif, Copaxone, and Tysabri for Active Multiple SclerosisTerminatedNCT01058005Phase 3Results posted
• Exercise Induced Pulmonary Hypertension in Systemic Sclerosis and Treatment With AmbrisentanCompletedNCT01051960Phase 4Results posted
• POC-MD MRI-based Trial in Relapsing-remitting Multiple SclerCompletedNCT01051817Phase 2Results posted
• Safety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) (BIIB019) in Participants Who Have Completed Study 205MS202 (NCT00870740) to Treat Relapsing Remitting Multiple SclerosisCompletedNCT01051349Phase 2Results posted
• A Study to Evaluate the Long-term Safety, Tolerability and Effect of Daily Oral Laquinimod 0.6 mg on Disease Course in Subjects With Relapsing Multiple SclerosisTerminatedNCT01047319Phase 3Results posted
• Patient Research Cohort: Rapidly Evolving Multiple SclerosisCompletedNCT01044576Results posted
• A Clinical Trial of Ambrisentan and Tadalafil in Pulmonary Arterial Hypertension Associated With Systemic SclerosisCompletedNCT01042158Phase 4Results posted
• A Multicenter, Open-label, RebiSmart™ Autoinjector Ease of Use StudyCompletedNCT01036165Phase 3Results posted
• The REbif® vs Glatiramer Acetate in Relapsing Multiple Sclerosis Pharmacogenetics TrialCompletedNCT01034579Phase 4Results posted
• Effects of Training on Central Auditory Function in Multiple SclerosisCompletedNCT01023074Not applicableResults posted
• Prospective Observational Long-term Safety Registry of Multiple Sclerosis Participants Who Have Participated in Cladribine Clinical TrialsCompletedNCT01013350Results posted
• Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of ACT-128800 in Patients With Relapsing-remitting Multiple SclerosisCompletedNCT01006265Phase 2Results posted
• Defining the Anti-inflammatory Role of Lipoic Acid in Multiple SclerosisCompletedNCT00997438Phase 1Results posted
• A Study To Evaluate the Long-Term Safety, Tolerability and Effect on Disease CourseTerminatedNCT00988052Phase 3Results posted
• Impact of Armodafinil on Neurocognition and Cognitive Fatigue in Multiple Sclerosis (MS)CompletedNCT00981084Phase 2/3Results posted
• Escitalopram (Lexapro) for Depression MS or ALSCompletedNCT00965497Phase 3Results posted
• The Multicenter, Open-label, Single-use Autoinjector Convenience StudyCompletedNCT00958009Phase 3Results posted
• Clinical Trial of Idebenone in Primary Progressive Multiple Sclerosis (IPPoMS)CompletedNCT00950248Phase 1/2Results posted
• Safety of New Formulation of Glatiramer AcetateCompletedNCT00947752Phase 3Results posted
• Drug-Drug Interaction of Cladribine and Pantoprazole in Multiple Sclerosis SubjectsCompletedNCT00938366Phase 1Results posted
• Comparison of 1.5T vs. 3T Protocols After Treatment With Glatiramer Acetate (GA)CompletedNCT00937157Not applicableResults posted
• Open-Label, Safety and Tolerability Extension Study of KNS-760704 in Amyotrophic Lateral Sclerosis (ALS) (CL211)CompletedNCT00931944Phase 2Results posted
• Efficacy of Clean Intermittent Catheterization (CIC) in Multiple Sclerosis (MS) Patients With Bladder DysfunctionTerminatedNCT00913510Not applicableResults posted
• Efficacy and Safety Study of Peginterferon Beta-1a in Participants With Relapsing Multiple SclerosisCompletedNCT00906399Phase 3Results posted
• A Study Comparing the Effectiveness and Safety of Teriflunomide and Interferon Beta-1a in Patients With Relapsing Multiple SclerosisCompletedNCT00883337Phase 3Results posted
• A Study of Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)CompletedNCT00882999Phase 2Results posted
• Rivastigmine in Multiple Sclerosis Patients With Cognitive ImpairmentTerminatedNCT00881205Phase 4Results posted
• Safety, Tolerability, Efficacy and Optimal Dose Finding Study of BAF312 in Patients With Relapsing-remitting Multiple SclerosisCompletedNCT00879658Phase 2Results posted
• Efficacy and Tolerability of Tauroursodeoxycholic Acid in Amyotrophic Lateral SclerosisCompletedNCT00877604Phase 2Results posted
• A Prospective, Open-label, Non-randomized, Clinical Trial to Determine if Natalizumab (Tysabri®) Improves Ambulatory Measures in Relapsing-remitting Multiple Sclerosis (RRMS) PatientsCompletedNCT00871780Phase 4Results posted
• Safety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) in Participants With Multiple Sclerosis Who Have Completed Study 205MS201 (NCT00390221) to Treat Relapsing-Remitting Multiple SclerosisCompletedNCT00870740Phase 2Results posted
• Safety and Efficacy of TRO19622 as add-on Therapy to Riluzole Versus Placebo in Treatment of Patients Suffering From ALSCompletedNCT00868166Phase 3Results posted
• Expiratory Muscle Training for Persons With Neurodegenerative DiseaseCompletedNCT00856518Phase 2/3Results posted
• Atacicept in Multiple Sclerosis Extension Study, Phase IITerminatedNCT00853762Phase 2Results posted
• Open-Label Study of Oral Treprostinil in Digital UlcersTerminatedNCT00848107Phase 2Results posted
• Trial of Ginkgo as a Treatment for Cognitive Problems in Multiple SclerosisCompletedNCT00841321Phase 2Results posted
• Safety of Polyphenon E in Multiple Sclerosis Pilot StudyCompletedNCT00836719Phase 1Results posted
• BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS)CompletedNCT00835770Phase 3Results posted
• Evaluate the Safe and Effective Use of the Avonex® Single-Use Autoinjector in Multiple Sclerosis SubjectsCompletedNCT00828204Phase 3Results posted
• Study to Investigate the Safety and Efficacy of Lithium in Volunteers With Amyotrophic Lateral Sclerosis (ALS)TerminatedNCT00818389Phase 2/3Results posted
• Long-term Follow-Up of Patients Who Participated in Study 27025 (REFLEX)CompletedNCT00813709Phase 3Results posted
• Long Term Safety of Teriflunomide When Added to Interferon-Beta or Glatiramer Acetate in Patients With Multiple SclerosisCompletedNCT00811395Phase 2Results posted
• Long Term Safety and Efficacy Study of Teriflunomide 7 mg or 14 mg in Patients With Relapsing-Remitting Multiple SclerosisCompletedNCT00803049Phase 3Results posted
• A Multi-Center Controlled Screening Trial of Safety and Efficacy of Lithium Carbonate in Subjects With Amyotrophic Lateral Sclerosis (ALS)CompletedNCT00790582Phase 2Results posted
• Efficacy and Safety of RAD001 in Patients Aged 18 and Over With Angiomyolipoma Associated With Either Tuberous Sclerosis Complex (TSC) or Sporadic Lymphangioleiomyomatosis (LAM)CompletedNCT00790400Phase 3Results posted
• Efficacy and Safety of Everolimus (RAD001) in Patients of All Ages With Subependymal Giant Cell Astrocytoma Associated With Tuberous Sclerosis Complex (TSC)(EXIST-1)CompletedNCT00789828Phase 3Results posted
• A Clinical Demonstration of EEG Brain-computer Interface for ALS PatientsCompletedNCT00786032Results posted
• Immunogenicity and Safety of Subcutaneously-administered Avonex (Interferon Beta-1a) in Multiple Sclerosis (MS) PatientsTerminatedNCT00784836Phase 3Results posted
• Duloxetine for Multiple Sclerosis PainCompletedNCT00755807Phase 3Results posted
• American Ginseng Treatment for Multiple Sclerosis Related FatigueCompletedNCT00754832Phase 2Results posted
• An Efficacy Study of Teriflunomide in Participants With Relapsing Multiple SclerosisCompletedNCT00751881Phase 3Results posted
• An Extension Study of LAQ/5062 Exploring the Long Term Safety, Tolerability and Clinical Effect Parameters During the DiseaseTerminatedNCT00745615Phase 2Results posted
• 12-week Study to Evaluate RebiSmart™ Suitability for Self Injection in Relapsing Multiple Sclerosis.CompletedNCT00735007Phase 3Results posted
• This Was an Open-label, Single-arm Extension Study (CFTY720D2306E1) to a Double-blind, Randomized Multicenter, Placebo-controlled, Parallel-group Core Study (CFTY720D2306) in PPMS.TerminatedNCT00731692Phase 3Results posted
• Oral Cladribine in Early Multiple Sclerosis (MS)CompletedNCT00725985Phase 3Results posted
• A Study of Sativex® for Relief of Spasticity in Subjects With Multiple Sclerosis.CompletedNCT00711646Phase 3Results posted
• Imatinib Mesylate to Treat Skin Changes in Patients With Chronic Graft-Versus-Host DiseaseCompletedNCT00702689Phase 2Results posted
• Evaluate the Maintenance of Effect After Long-term Treatment With Sativex® in Subjects With Symptoms of Spasticity Due to Multiple SclerosisCompletedNCT00702468Phase 3Results posted
• Reduced Intensity Transplant in Medically Refractory Systemic Lupus Erythematosus (SLE) and Systemic Sclerosis (SSc)TerminatedNCT00684255Phase 1Results posted
• Cannabis for Spasticity in Multiple SclerosisTerminatedNCT00682929Phase 1/2Results posted
• A Study of the Safety and Effectiveness of Sativex®, for the Relief of Symptoms of Spasticity in Subjects, From Phase B, With Multiple Sclerosis (MS)CompletedNCT00681538Phase 3Results posted
• A Parallel Group Study to Compare Sativex® With Placebo in the Treatment of Detrusor Overactivity in Patients With Multiple SclerosisCompletedNCT00678795Phase 3Results posted
• Cognitive Behavioural Therapy Software for the Treatment of Depression in People With Multiple SclerosisCompletedNCT00678496Not applicableResults posted

← Sclerosis overview